Work

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis

Year: 2006
Type: article
Abstract: Tyrosine kinases play a central role in the activation of signal transduction pathways and cellular responses that mediate the pathogenesis of rheumatoid arthritis. Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor developed to treat Bcr/Abl-expressing leukemias and subsequently found to treat c-Kit-expressing gastrointestinal stromal tumors. We demonstrate that imatinib potently prevents and treats murine collagen-induced arthritis (CIA). We further show that micromolar concentrations of imatinib abrogate multiple signal transduction pathways implicated in RA pathogenesis, including mast cell c-Kit signaling and TNF-alpha release, macrophage c-Fms activation and cytokine production, and fibroblast PDGFR signaling and proliferation. In our studies, imatinib attenuated PDGFR signaling in fibroblast-like synoviocytes (FLSs) and TNF-alpha production in synovial fluid mononuclear cells (SFMCs) derived from human RA patients. Imatinib-mediated inhibition of a spectrum of signal transduction pathways and the downstream pathogenic cellular responses may provide a powerful approach to treat RA and other inflammatory diseases.
Authors: R. T. Paniagua, O. Sharpe, P. P. Ho, S. M. Chan, A. Chang, J. P. Higgins, B. H. Tomooka, F. M. Thomas, J. J. Song, S. B. Goodman, D. M. Lee, M. C. Genovese, P. J. Utz, L. Steinman, W. H. Robinson
Language: English
Subfield: Rheumatology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2141138459
FWCI: 16.47
Cites: 73
Cited by: 215
Related to: 10